MedTrace Logo

Preoperative Window of Endocrine Therapy Provides Information to Increase Compliance

NCT01614210 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 52

Last updated 2018-08-01

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to see if tumors respond to endocrine therapy by taking a total of 21 doses of Tamoxifen before and after surgery. Tamoxifen is currently approved by the FDA (Food and Drug Administration) for use in the treatment of hormone positive breast cancer.

Conditions

  • Newly Diagnosed Hormone Positive Clinical Stage 1 or 2 Breast Cancer

Interventions

DRUG

Tamoxifen

All patients will take tamoxifen 20 mg po daily for 7 days prior to surgery and for 14 days after surgery.

PROCEDURE

Breast cancer surgery

Breast cancer surgery

Sponsors & Collaborators

Principal Investigators

  • Leigh Neumayer, MD · Huntsman Cancer Institute

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-08-31
Primary Completion
2016-11-30
Completion
2016-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01614210 on ClinicalTrials.gov